International Value Advisers Has Trimmed Baidu Adr (BIDU) Stake; Invesco LTD Cut Nektar Therapeutics (NKTR) Stake By $97.60 Million

May 27, 2018 - By Orlando Nugent

Nektar Therapeutics (NASDAQ:NKTR) Logo

Invesco Ltd decreased Nektar Therapeutics (NKTR) stake by 45.79% reported in 2017Q4 SEC filing. Invesco Ltd sold 1.65M shares as Nektar Therapeutics (NKTR)’s stock rose 80.22%. The Invesco Ltd holds 1.96 million shares with $116.96 million value, down from 3.61M last quarter. Nektar Therapeutics now has $13.71B valuation. The stock decreased 0.77% or $0.62 during the last trading session, reaching $79.96. About 1.65M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since May 27, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

International Value Advisers Llc decreased Baidu Inc. Adr (BIDU) stake by 0.58% reported in 2017Q4 SEC filing. International Value Advisers Llc sold 2,384 shares as Baidu Inc. Adr (BIDU)’s stock declined 3.38%. The International Value Advisers Llc holds 405,470 shares with $94.97 million value, down from 407,854 last quarter. Baidu Inc. Adr now has $85.02B valuation. The stock increased 1.46% or $3.52 during the last trading session, reaching $243.8. About 5.06 million shares traded or 47.82% up from the average. Baidu, Inc. (NASDAQ:BIDU) has risen 36.72% since May 27, 2017 and is uptrending. It has outperformed by 25.17% the S&P500.

Since December 13, 2017, it had 0 insider buys, and 33 sales for $94.57 million activity. Thomsen Jillian B. sold 13,881 shares worth $1.41 million. Labrucherie Gil M sold $288,382 worth of Nektar Therapeutics (NASDAQ:NKTR) on Friday, February 16. Shares for $338,563 were sold by Hora Maninder on Wednesday, May 16. 4,917 shares valued at $410,029 were sold by Nicholson John on Wednesday, May 16. Another trade for 12,791 shares valued at $1.07M was sold by ROBIN HOWARD W. $2.07M worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by CHESS ROBERT. Another trade for 3,435 shares valued at $286,445 was made by Doberstein Stephen K on Wednesday, May 16.

Investors sentiment decreased to 1.19 in 2017 Q4. Its down 0.21, from 1.4 in 2017Q3. It fall, as 18 investors sold NKTR shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Jennison Associates Limited Com stated it has 253,416 shares. Redmile Group Ltd Liability Com invested in 5,327 shares. Adage Cap Prtnrs Grp Inc Limited Liability reported 139,000 shares stake. Opaleye Mgmt invested 1.53% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Comerica Comml Bank accumulated 0.08% or 161,656 shares. Rhenman Ptnrs Asset Mgmt owns 353,503 shares or 2.85% of their US portfolio. New York-based Jane Street Grp Lc has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Fmr Limited Liability accumulated 11.24M shares or 0.08% of the stock. Northern Corporation accumulated 0.03% or 1.88M shares. Eagle Asset Mngmt Inc stated it has 1.02M shares. Tocqueville Asset Mgmt Lp owns 0.21% invested in Nektar Therapeutics (NASDAQ:NKTR) for 308,062 shares. Cibc Asset Mngmt stated it has 5,415 shares or 0% of all its holdings. Amer Group holds 118,976 shares or 0.02% of its portfolio. University Of Notre Dame Du Lac accumulated 0.82% or 66,200 shares. Panagora Asset Inc owns 0.14% invested in Nektar Therapeutics (NASDAQ:NKTR) for 636,245 shares.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: “Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise” on May 16, 2018, also Benzinga.com with their article: “The Week Ahead In Biotech: ASCO Presentations In The Spotlight” published on May 26, 2018, Nasdaq.com published: “3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies …” on May 11, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Fool.com and their article: “Here’s Why Nektar Therapeutics Fell as Much as 11.1% Today” published on May 17, 2018 as well as Nasdaq.com‘s news article titled: “Why Dell Technologies, Nektar Therapeutics, and Westport Fuel Systems Jumped Today” with publication date: May 18, 2018.

Invesco Ltd increased Qualcomm Inc (NASDAQ:QCOM) stake by 643,360 shares to 25.06M valued at $1.60B in 2017Q4. It also upped Owens & Minor Inc New (NYSE:OMI) stake by 299,501 shares and now owns 1.46 million shares. Lilly Eli & Co (NYSE:LLY) was raised too.

Among 11 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 28 analyst reports since August 6, 2015 according to SRatingsIntel. Mizuho maintained the shares of NKTR in report on Friday, April 6 with “Buy” rating. Jefferies maintained the shares of NKTR in report on Wednesday, November 8 with “Buy” rating. J.P. Morgan maintained the stock with “Buy” rating in Tuesday, July 18 report. The stock has “Buy” rating by Roth Capital on Thursday, July 20. The company was reinitiated on Monday, April 2 by H.C. Wainwright. The rating was maintained by Canaccord Genuity on Friday, May 11 with “Buy”. The stock has “Buy” rating by Roth Capital on Tuesday, May 30. The rating was initiated by Canaccord Genuity on Thursday, November 9 with “Buy”. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Monday, November 13 by Roth Capital. Roth Capital maintained the shares of NKTR in report on Wednesday, August 30 with “Buy” rating.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on August, 14. They expect $0.27 earnings per share, up 169.23% or $0.66 from last year’s $-0.39 per share. NKTR’s profit will be $46.28M for 74.04 P/E if the $0.27 EPS becomes a reality. After $-0.60 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -145.00% EPS growth.

Among 27 analysts covering Baidu (NASDAQ:BIDU), 13 have Buy rating, 2 Sell and 12 Hold. Therefore 48% are positive. Baidu had 71 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was downgraded by Nomura on Friday, January 22 to “Neutral”. The rating was maintained by Deutsche Bank with “Hold” on Wednesday, September 9. The stock of Baidu, Inc. (NASDAQ:BIDU) has “Buy” rating given on Sunday, May 20 by Oppenheimer. JP Morgan maintained it with “Neutral” rating and $225 target in Monday, October 30 report. As per Wednesday, January 11, the company rating was initiated by Bernstein. On Wednesday, September 28 the stock rating was downgraded by Deutsche Bank to “Hold”. The firm earned “Outperform” rating on Tuesday, October 31 by Oppenheimer. The stock of Baidu, Inc. (NASDAQ:BIDU) earned “Neutral” rating by Macquarie Research on Monday, October 31. Jefferies maintained it with “Buy” rating and $291.0 target in Friday, October 27 report. On Wednesday, February 14 the stock rating was upgraded by Daiwa Securities to “Outperform”.

Analysts await Baidu, Inc. (NASDAQ:BIDU) to report earnings on July, 26. They expect $2.15 EPS, up 6.44% or $0.13 from last year’s $2.02 per share. BIDU’s profit will be $749.77M for 28.35 P/E if the $2.15 EPS becomes a reality. After $2.25 actual EPS reported by Baidu, Inc. for the previous quarter, Wall Street now forecasts -4.44% negative EPS growth.

More notable recent Baidu, Inc. (NASDAQ:BIDU) news were published by: Nasdaq.com which released: “This Baidu Inc (ADR) Dip Is Another Long Trade Opportunity for Easy Profits” on May 21, 2018, also Finance.Yahoo.com with their article: “The Selloff in Baidu Inc Stock Is a Golden Buying Opportunity” published on May 24, 2018, Fool.com published: “Baidu’s AI Brain Drain Continues” on May 23, 2018. More interesting news about Baidu, Inc. (NASDAQ:BIDU) were released by: Nasdaq.com and their article: “When Will Baidu Stock Hit a New All-Time High?” published on May 22, 2018 as well as Seekingalpha.com‘s news article titled: “Baidu’s AI Drive Hits Speed Bump With COO Departure” with publication date: May 21, 2018.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: